Cargando…
Advanced Medical Devices for Preparation and Administration of Chemotherapeutic Agents: Results from a Multi-Dimensional Evaluation
PURPOSE: To evaluate the incremental benefits concerning the implementation of closed-system medical devices for the preparation and administration of chemotherapy agents (integrated or not with traceable workflow), within an Italian clinical practice, in which the use of such technologies is not st...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718866/ https://www.ncbi.nlm.nih.gov/pubmed/33293839 http://dx.doi.org/10.2147/CEOR.S267283 |
_version_ | 1783619572809596928 |
---|---|
author | Ferrario, Lucrezia Schettini, Fabrizio Garagiola, Elisabetta Cecchi, Adriana Lugoboni, Lucia Serra, Paolo Porazzi, Emanuele Foglia, Emanuela |
author_facet | Ferrario, Lucrezia Schettini, Fabrizio Garagiola, Elisabetta Cecchi, Adriana Lugoboni, Lucia Serra, Paolo Porazzi, Emanuele Foglia, Emanuela |
author_sort | Ferrario, Lucrezia |
collection | PubMed |
description | PURPOSE: To evaluate the incremental benefits concerning the implementation of closed-system medical devices for the preparation and administration of chemotherapy agents (integrated or not with traceable workflow), within an Italian clinical practice, in which the use of such technologies is not standardized. METHODOLOGY: Four Scenarios, implying different levels of technologies introduction, were analyzed, based on the presence and/or absence of closed systems and traceable workflow, in the preparation and in the administration phase. A literature review was conducted, in order to retrieve efficacy and safety measures. Economic and organizational benefits, assuming a hospitals perspective, were assessed by means of health-economics tools, considering 27,660 (±695.86) drugs on average prepared, on an annual basis, by 12 hospitals involved. The typology of medical devices and other devices/equipment used, the human resources involved, and the time spent for the preparation and administration phases were collected. RESULTS: Literature stated that the introduction of advanced technologies (CSTDs in the preparation phase, closed-system in the administration phase, both integrated by a traceable workflow) could: i) decrease surface contamination (12.24% vs 26.39%, P<0.001) and ii) improve the capability to identify dosage errors (7% vs 0.096%, P<0.05). The above technologies presented the best trade-off between cost sustained and efficacy gained. Despite marginal investments (ranging from +1% to +6%) being required for their acquisition, an organizational saving equal to more than 1,000 working hours emerged, which could be spent on other hospital activities. CONCLUSION: The implementation of closed systems, integrated with a traceable workflow grounding on gravimetric control, may be considered a valid technological alternative within the investigated setting. The marginal incremental costs could be absorbed already in the first year after their introduction, in particular, because of the potential time saving in using closed systems in both the preparation and administration phases, demonstrating the sustainability and feasibility of such advanced technologies. |
format | Online Article Text |
id | pubmed-7718866 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-77188662020-12-07 Advanced Medical Devices for Preparation and Administration of Chemotherapeutic Agents: Results from a Multi-Dimensional Evaluation Ferrario, Lucrezia Schettini, Fabrizio Garagiola, Elisabetta Cecchi, Adriana Lugoboni, Lucia Serra, Paolo Porazzi, Emanuele Foglia, Emanuela Clinicoecon Outcomes Res Original Research PURPOSE: To evaluate the incremental benefits concerning the implementation of closed-system medical devices for the preparation and administration of chemotherapy agents (integrated or not with traceable workflow), within an Italian clinical practice, in which the use of such technologies is not standardized. METHODOLOGY: Four Scenarios, implying different levels of technologies introduction, were analyzed, based on the presence and/or absence of closed systems and traceable workflow, in the preparation and in the administration phase. A literature review was conducted, in order to retrieve efficacy and safety measures. Economic and organizational benefits, assuming a hospitals perspective, were assessed by means of health-economics tools, considering 27,660 (±695.86) drugs on average prepared, on an annual basis, by 12 hospitals involved. The typology of medical devices and other devices/equipment used, the human resources involved, and the time spent for the preparation and administration phases were collected. RESULTS: Literature stated that the introduction of advanced technologies (CSTDs in the preparation phase, closed-system in the administration phase, both integrated by a traceable workflow) could: i) decrease surface contamination (12.24% vs 26.39%, P<0.001) and ii) improve the capability to identify dosage errors (7% vs 0.096%, P<0.05). The above technologies presented the best trade-off between cost sustained and efficacy gained. Despite marginal investments (ranging from +1% to +6%) being required for their acquisition, an organizational saving equal to more than 1,000 working hours emerged, which could be spent on other hospital activities. CONCLUSION: The implementation of closed systems, integrated with a traceable workflow grounding on gravimetric control, may be considered a valid technological alternative within the investigated setting. The marginal incremental costs could be absorbed already in the first year after their introduction, in particular, because of the potential time saving in using closed systems in both the preparation and administration phases, demonstrating the sustainability and feasibility of such advanced technologies. Dove 2020-12-01 /pmc/articles/PMC7718866/ /pubmed/33293839 http://dx.doi.org/10.2147/CEOR.S267283 Text en © 2020 Ferrario et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Ferrario, Lucrezia Schettini, Fabrizio Garagiola, Elisabetta Cecchi, Adriana Lugoboni, Lucia Serra, Paolo Porazzi, Emanuele Foglia, Emanuela Advanced Medical Devices for Preparation and Administration of Chemotherapeutic Agents: Results from a Multi-Dimensional Evaluation |
title | Advanced Medical Devices for Preparation and Administration of Chemotherapeutic Agents: Results from a Multi-Dimensional Evaluation |
title_full | Advanced Medical Devices for Preparation and Administration of Chemotherapeutic Agents: Results from a Multi-Dimensional Evaluation |
title_fullStr | Advanced Medical Devices for Preparation and Administration of Chemotherapeutic Agents: Results from a Multi-Dimensional Evaluation |
title_full_unstemmed | Advanced Medical Devices for Preparation and Administration of Chemotherapeutic Agents: Results from a Multi-Dimensional Evaluation |
title_short | Advanced Medical Devices for Preparation and Administration of Chemotherapeutic Agents: Results from a Multi-Dimensional Evaluation |
title_sort | advanced medical devices for preparation and administration of chemotherapeutic agents: results from a multi-dimensional evaluation |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718866/ https://www.ncbi.nlm.nih.gov/pubmed/33293839 http://dx.doi.org/10.2147/CEOR.S267283 |
work_keys_str_mv | AT ferrariolucrezia advancedmedicaldevicesforpreparationandadministrationofchemotherapeuticagentsresultsfromamultidimensionalevaluation AT schettinifabrizio advancedmedicaldevicesforpreparationandadministrationofchemotherapeuticagentsresultsfromamultidimensionalevaluation AT garagiolaelisabetta advancedmedicaldevicesforpreparationandadministrationofchemotherapeuticagentsresultsfromamultidimensionalevaluation AT cecchiadriana advancedmedicaldevicesforpreparationandadministrationofchemotherapeuticagentsresultsfromamultidimensionalevaluation AT lugobonilucia advancedmedicaldevicesforpreparationandadministrationofchemotherapeuticagentsresultsfromamultidimensionalevaluation AT serrapaolo advancedmedicaldevicesforpreparationandadministrationofchemotherapeuticagentsresultsfromamultidimensionalevaluation AT porazziemanuele advancedmedicaldevicesforpreparationandadministrationofchemotherapeuticagentsresultsfromamultidimensionalevaluation AT fogliaemanuela advancedmedicaldevicesforpreparationandadministrationofchemotherapeuticagentsresultsfromamultidimensionalevaluation |